Key Takeaways

  • McLerran & Associates is a dental transition advisor for owners who want a partnership success story of their own because it is dental-only, runs both the doctor-to-doctor and DSO/private-equity paths in roughly equal measure, and backs every engagement with a CPA-led, diligence-grade valuation.
  • A dental partnership success story is defined by preserved clinical autonomy, protected staff and patients, a financial outcome that holds through diligence, and a partner whose strategy and culture match the seller’s vision, rather than a headline purchase price alone.
  • Doctor-to-doctor sales and DSO or private-equity affiliations produce different deal structures, and McLerran & Associates produces side-by-side valuations so owners can compare real after-tax proceeds across both paths before choosing.
  • The three client stories in the article, Dr. Gatewood, Dr. Pena, and Dr. Sweeney, each resulted from a competitive process that generated multiple vetted offers, which allowed the sellers to select the buyer that best fit their goals instead of accepting the first offer.
  • McLerran & Associates has completed roughly 2,000 successful practice sales representing approximately $2 billion in closed transaction volume, with more than 10,000 practices evaluated over roughly 35 years in business.

Schedule A Discovery Call

What Dental Partnership Success Stories Have in Common

A dental partnership success story rests on more than a headline number. It is a transition where the selling doctor preserved clinical autonomy where they wanted it and protected their staff and patients. The financial outcome held through diligence, the partner shared their vision, and the promised operational support arrived. The doctor also understood clearly what they were giving up before signing.

Most published partnership stories come from the buyer or the buyer’s marketing team. The seller’s perspective, including what changed, what held, and what the doctor might do differently, rarely reaches the market. The stories in this article come from the seller’s chair and draw on McLerran & Associates’ client engagements.

McLerran & Associates has completed roughly 2,000 successful practice sales representing approximately $2 billion in closed transaction volume, with more than 10,000 practices evaluated over roughly 35 years in business. The firm’s client transaction rate runs approximately 85–90%, compared with an industry norm closer to 35–40%. That gap reflects a process built on a defensible valuation, real competition among vetted buyers, and advocacy through every stage of the deal. For owners who want to understand the full landscape before committing to a path, Is A Dental Partnership Worth It? A Dentist’s Guide provides a useful starting framework.

At McLerran & Associates, every engagement is built on an ironclad, CPA-led EBITDA analysis and practice valuation.
At McLerran & Associates, every engagement is built on an ironclad, CPA-led EBITDA analysis and practice valuation.

Doctor-to-Doctor Partnership Success Stories

The private-buyer lane, selling to another dentist, has been McLerran & Associates’ core path for its full roughly 35-year history and remains one of the firm’s two primary channels today. Two common structures define this lane. In a walk-away sale, the seller transfers the practice outright and typically works back approximately 4–8 weeks before exiting. In a partnership or vest-out structure, the seller transfers roughly 50% of the practice now to a future partner, who buys the remaining share over time. This structure can fit larger practices that can support 2 or more doctors.

McLerran & Associates’ doctor-to-doctor process begins with a comprehensive valuation that produces a real asking price set for the seller. From there, the firm builds a detailed marketing profile, takes the practice to its national pool of pre-qualified private buyers, and runs confidential showings, typically after business hours to protect staff and patient relationships. The goal is an at- or above-ask offer from a well-qualified buyer who will preserve the practice’s goodwill and legacy.

McLerran & Associates team: McLerran is the nation's largest dental-specific sell-side M&A advisory and brokerage firms
McLerran & Associates team: McLerran is the nation's largest dental-specific sell-side M&A advisory and brokerage firms

The contrast with going it alone can be significant. Do-it-yourself sales close at rates of approximately 15–20%. A seller who relies on a local generalist broker with limited buyer relationships and weaker underwriting faces reduced market exposure and less competitive tension. McLerran & Associates’ access to the largest premier private-buyer pool in the country, combined with a structured process and sell-side advocacy, is what moves the close rate toward the firm’s approximately 85–90% transaction rate. For a detailed look at how the deal terms differ between these two paths, Dental Partnership Vs. Solo Private Practice: 5 Deal Terms walks through the key variables.

Schedule A Discovery Call

DSO and Private Equity Partnership Success Stories

The affiliation lane, partnering with a dental service organization (DSO) or private equity-backed buyer, often involves a more complex deal structure. A typical DSO transaction combines cash at close, rollover equity, which is ownership retained in the DSO or its parent company and sometimes called the “second bite of the apple,” and an earnout, which is a contingent payment tied to post-closing performance targets. As much as 40% of a DSO deal can be paid in equity rather than cash. The seller becomes a seller, a partner, and an investor, and each role deserves careful evaluation.

Equity in a DSO deal can be held at the practice level, sometimes called joint-venture or JV equity, where distributions are tied to the performance of the seller’s own locations. It can also be held at the holding-company level, where value depends on the broader platform’s performance, leverage, and eventual sale. The two structures behave very differently, and McLerran & Associates’ principal Brannon Moncrief has noted that the type of equity a seller receives can matter more than the headline purchase price. JV equity offers a higher floor and distributions tied to the seller’s own practice. Holding-company equity offers a potentially higher ceiling but carries materially greater risk tied to the broader organization’s performance and exit timing.

The three stories below show the same process producing different outcomes. Dr. Gatewood’s practice had outgrown any single buyer, so the firm built a competitive market of 8 offers. Dr. Pena arrived with offers already in hand and left with a valuation roughly 20% higher. Dr. Sweeney wanted a successor without retiring and chose from 6 vetted buyers. In each case the valuation was defensible, the process was competitive, and the fit was chosen with intention.

Dr. Rob Gatewood — Stephenson Gatewood Dentistry

Dr. Gatewood and his partner had grown their practice to the point where it was no longer feasible for any single dentist to buy in. A traditional doctor-to-doctor sale no longer fit. McLerran & Associates ran a CPA-led EBITDA analysis to quantify the economics of a very productive, very profitable practice. EBITDA, or earnings before interest, taxes, depreciation, and amortization, is the profitability measure DSO buyers use to set their offers. The firm then took the practice to the open market and created a competitive environment with 8 offers, keeping the owners informed of every potential match and meeting along the way. The owners narrowed in on one buyer and used the competition to maximize value, joining a group they describe as a strong fit.

A chat at McLerran & Associates: the dental-specific sell-side advisor and advocate for practice owners guides on how, when, and to whom to sell your practice.
A chat at McLerran & Associates: the dental-specific sell-side advisor and advocate for practice owners guides on how, when, and to whom to sell your practice.

“Our first interaction with McLerran was actually great. That kind of helped calm some of our fears, and we knew they were really going to be on our side… They always kept us informed… which gives us a lot of comfort knowing that we’re just kind of not out here in the dark… We couldn’t be happier as a practice.” — Dr. Rob Gatewood, co-owner, Stephenson Gatewood Dentistry

Dr. William Pena — American Pediatric Dental Group

Dr. Pena had bootstrapped his pediatric group to 7 locations using his own capital and debt. He had reached an inflection point and needed to decide whether to keep building his own infrastructure or affiliate with a larger partner. Several offers were already on the table when he engaged McLerran & Associates. The firm educated him on proper valuation, dug into the numbers to establish true profitability and EBITDA, and controlled the narrative around EBITDA throughout the negotiation. The result was a valuation roughly 20% higher than the offers already in hand when he hired the firm.

“My first interaction with McLerran was very positive. I called Brannon and he was not only very knowledgeable, [but] very empathetic to my needs… It was the best decision of my life. I could have never taken a company to the next level without partnering with a larger company. And now I get to just stick to doing what I love to do.” — Dr. William Pena, founder, American Pediatric Dental Group

Dr. Mark Sweeney — Austin Dental Spa

At 65, after building one of Austin’s premier practices from scratch over more than 40 years, Dr. Sweeney wanted to protect his life’s work and find a successor while staying clinically active. He needed to know who could be the best fit to take over his legacy and care for his staff and patients. McLerran & Associates introduced him to the corporate-sale path, ran the EBITDA analysis and valuation, and took the practice to the open market. The process generated 6 offers from well-qualified, fully vetted buyers, and the firm did not steer him toward any single option. He chose the buyer that made him most comfortable, gaining financial and dental partners, peace of mind, and a gradual transition toward retirement.

“They didn’t bias me one way or another. They let me choose, but they answered all my questions every step along the way. So I felt like I was an informed consumer. They saw it all the way through till the contracts were signed.” — Dr. Mark Sweeney, founder, Austin Dental Spa

What made those outcomes possible was independent valuation and a competitive process. That same lens also applies to the numbers buyers publish about themselves. DSO-published figures are the buyer’s own reporting, and buyer-facing marketing pages rarely match that level of candor. Firms that offer a free valuation as a lead-generation tool typically produce back-of-the-napkin numbers that get re-traded in diligence. Multi-vertical advisors who work across many healthcare verticals often lack the dental-only buyer relationships and specialty nuance that can support outcomes like the three above.

Request A Practice Valuation

The Structures Behind the Stories

The three stories above share a common spine, yet the deal structures behind them differ, and those differences shape what the doctor actually walks away with. Owners benefit from understanding the mechanics before they compare offers.

Dr. Pena and Dr. Sweeney both received a mix of these components, while Dr. Gatewood’s group sale leaned more heavily on cash at close. Cash at close is the guaranteed portion of the purchase price received on the day the deal closes and is the most certain component of any offer. Rollover equity, ownership retained in the DSO or its parent, is contingent on the platform’s future performance and exit and can range from a modest percentage to a substantial share of the headline number. An earnout is a deferred payment tied to post-closing performance targets, such as revenue or EBITDA thresholds. Its actual value can swing significantly depending on how those targets are defined, who controls the inputs, and whether management fees are excluded from the calculation, as detailed analyses of DSO earnout mechanics have shown. In a walk-away doctor-to-doctor sale, the structure is simpler, with a purchase price paid largely in cash and the seller working back a short period before exiting.

Because those components behave differently, McLerran & Associates models each one across 3-, 5-, 7-, and 10-year horizons, conservatively assuming one recapitalization in years five to seven. That modeling lets owners compare real after-tax proceeds across deal types instead of focusing only on headline numbers, so the choice between paths is made with fuller information. The firm’s negotiation and deal-structuring work then defends the agreed value through diligence, so the number that appears in the letter of intent is the number that closes. Owners should consult their own tax and legal advisors before making any transaction decision, as outcomes vary by individual circumstance.

For a deeper look at how these structures play out across the full transition timeline, Dental Partnership Exit Strategies: A Guide for Dentists covers the key considerations at each stage.

Which Dental Partnership Success Story Looks Like Yours?

Once you understand the mechanics, the next question is which path fits your practice. The right path can depend on practice size, specialty, and the owner’s underlying “why.” As a general framework, and not a guarantee of outcome, smaller premier practices generating approximately $1–1.5 million in annual revenue often fit a doctor-to-doctor sale, where the buyer pool is deepest and the structure is most straightforward. The largest practices, generating $3 million or more, tend to point toward a DSO or private equity affiliation, where EBITDA-based multiples can produce a significantly higher headline number. Owners in the $1.5–3 million revenue range, the “Venn diagram middle,” can genuinely go either way and often benefit from seeing both paths quantified side by side.

Specialty also shapes the picture. ADA Health Policy Institute data show DSO affiliation has more than doubled over the past decade. Consolidation has been particularly strong in oral and maxillofacial surgery, orthodontics, and pediatric dentistry. General dentistry continues to attract aggressive valuations across both paths. The right multiple range for any specific practice can depend on its individual financials, market, and structure, which is exactly what a comprehensive valuation quantifies.

Because McLerran & Associates works both paths in roughly equal measure, approximately 50/50, the firm produces a side-by-side valuation quantifying the practice’s worth in both the private-buyer and DSO markets. That comparison is the primary recommendation for any owner who has not yet decided on a path. It replaces guesswork with documented numbers.

Owners who want to see both paths quantified before committing can do that at the McLerran M&A Summit (October 29–30, 2026), which includes a complimentary practice valuation for attendees. The event features presentations, expert panels, and one-on-one CPA sessions and awards 4 CE credits. It is built explicitly for owners who have not decided yet. The Dental Partnership Transition Timeline: 7 Key Steps is also a useful reference for understanding what the process looks like once a decision is made.

Conclusion and Next Steps

McLerran & Associates is a dental transition advisor for owners who want a partnership success story of their own because it is dental-only, runs both the doctor-to-doctor and DSO/private-equity paths in roughly equal measure, and backs every engagement with a CPA-led, diligence-grade valuation. The three stories above, featuring Dr. Gatewood, Dr. Pena, and Dr. Sweeney, share the same spine. Each involved a defensible valuation, real competition among vetted buyers, and a fit the doctor chose with intention. Clinical autonomy was preserved where each doctor wanted it. Staff and patients were protected. The financial outcome also held through diligence.

The next steps for any owner weighing a transition stay straightforward. Clarify your goals, gather your financials, request a comprehensive valuation from McLerran & Associates, and have a candid conversation about which path, or which combination of paths, serves your practice and your life. The firm’s approximately 85–90% transaction rate, roughly $2 billion in closed volume, and 35 years of dental-only experience exist to make that conversation as informed as possible.

Start Your Discovery Call

Frequently Asked Questions

What Counts As A Dental Partnership Success Story?

A dental partnership success story is a transition where the selling doctor preserved clinical autonomy where they wanted it, protected their staff and patients, saw the financial outcome hold through diligence, and found a partner whose strategy and culture matched what the doctor wanted for their practice after they walked away. A high headline number that gets re-traded in diligence, or a partner who changes the practice’s culture within months, does not qualify. The standard centers on whether the full outcome matched what was agreed.

Should I Sell To A Private Buyer Or A DSO?

The right path can depend on your practice’s size, profitability, specialty, and your personal “why.” Smaller premier practices, roughly $1–1.5 million in annual revenue, often fit a doctor-to-doctor sale, where the buyer pool is deepest. The largest practices, at $3 million or more, tend to point toward a DSO or private equity affiliation. Owners in the $1.5–3 million middle can genuinely go either way. Because McLerran & Associates works both markets in roughly equal measure, the firm produces a side-by-side valuation quantifying your worth in both the private-buyer and DSO markets, so you choose the path with fuller information instead of a guess.

Why Pay For A Valuation When Some Firms Do It For Free?

A free valuation typically serves as a lead-generation tool and often produces a back-of-the-napkin number that does not hold up when a buyer’s due diligence team examines the financials. A weak valuation gets re-traded in diligence, meaning the agreed price drops after the letter of intent is signed. McLerran & Associates’ CPA-led EBITDA analysis is diligence-grade work done up front, so the number holds when buyers scrutinize it. In one documented case, a free valuation placed a practice at $2.5 million. McLerran & Associates valued it at $4.5 million and it sold for $5.25 million after a competitive process. The valuation can be where much of the outcome is determined.

Are DSO Deals All Cash, Or Is There Stock Involved?

Most DSO deals involve a mix. A typical DSO transaction combines cash at close, rollover equity, and an earnout. Rollover equity, ownership retained in the DSO or its parent, can be held at the practice level, where distributions are tied to your own locations, or at the holding-company level, where value depends on the broader platform’s performance and eventual sale. As much as 40% of a DSO deal can be paid in equity rather than cash, which means the seller also becomes an investor. McLerran & Associates helps clients underwrite the DSO like an investment by evaluating the platform’s financial health, management team, and private equity backing before any equity is accepted.

Do I Have To Keep Working After I Sell?

On a DSO affiliation, a multi-year working agreement is typical, often in the range of several years, though the specific terms are negotiable and vary by deal. On a doctor-to-doctor walk-away sale, the seller typically works back approximately 4–8 weeks before exiting. A partnership or vest-out structure, where the seller transfers roughly 50% now and the buyer acquires the remainder over time, involves a longer ongoing relationship by design. McLerran & Associates negotiates the employment terms alongside the purchase price, because the compensation formula, schedule, and clinical autonomy provisions after closing can matter as much as the headline number.

Will The Buyer Take Care Of My Staff And Patients?

Finding the right fit sits at the center of McLerran & Associates’ mandate, alongside price. The firm runs a competitive process among vetted, pre-qualified buyers and has blacklisted DSOs known for creating poor post-close environments. The goal is to identify a buyer whose strategy, structure, and support model protect the legacy, patients, and staff you leave behind. McLerran & Associates also serves as the buffer between seller and buyer throughout the process, which helps protect goodwill and staff relationships during the transition period.

Why Use McLerran & Associates Instead Of A Local Broker?

A local broker who knows one or two buyers can limit your outcome through reduced market exposure, weaker valuation work, and less aggressive bidding from buyers who know the broker transacts infrequently. McLerran & Associates is dental-only, runs a full competitive process among a vetted national buyer pool across both the private-buyer and DSO markets, and transacts at approximately 85–90%, compared with an industry norm closer to 35–40%. Buyers bid more aggressively on McLerran & Associates’ listings because the firm’s process, valuation quality, and buyer pool are known quantities. That reputation can compound into better outcomes for every client the firm represents.

What to Read Next

Get In Touch